Fibromyalgia and Medical Cannabis: The Evidence

What Is Fibromyalgia and Why Is Treatment Difficult?

• Fibromyalgia is a chronic widespread pain condition characterised by musculoskeletal pain, fatigue, cognitive difficulties and sleep disturbances affecting an estimated 2–4% of the UK population.
• The condition is poorly understood mechanistically; central sensitisation — an amplification of pain signals in the central nervous system — is currently the leading hypothesis.
• Conventional treatments including amitriptyline, duloxetine, pregabalin and physiotherapy provide only partial relief for the majority of fibromyalgia patients.
• High rates of treatment failure and comorbid depression, anxiety and insomnia make fibromyalgia patients one of the most common groups seeking medical cannabis in the UK.

The unmet need in fibromyalgia is substantial; many patients have cycled through multiple drug combinations with limited success before considering medical cannabis as an alternative.

How Cannabis May Help Fibromyalgia Patients

• Cannabinoids interact with CB1 and CB2 receptors in the central and peripheral nervous system, modulating pain signal transmission and potentially reducing central sensitisation.
• THC has demonstrated analgesic properties in clinical trials for neuropathic and central pain, both of which are relevant to the fibromyalgia pain profile.
• CBD may contribute to sleep improvement and anxiety reduction, addressing key comorbidities that worsen fibromyalgia symptom burden.
• The entourage effect hypothesis suggests that full-spectrum cannabis preparations containing multiple cannabinoids and terpenes may produce superior outcomes compared to isolated compounds.

While the evidence base for cannabis in fibromyalgia is not yet at the level required for NICE approval, observational and patient-reported data consistently show meaningful symptom improvements.

Clinical Evidence and UK Prescribing for Fibromyalgia

• A 2019 Israeli observational study of 367 fibromyalgia patients treated with cannabis reported significant reductions in pain intensity and improved quality of life after six months.
• UK specialist clinics report fibromyalgia as one of the top three indications for medical cannabis prescriptions, reflecting both prevalence and treatment failure rates.
• The MCAP (Medical Cannabis Access Programme) has collected real-world outcome data from UK fibromyalgia patients, with published results showing improvements in pain, sleep and anxiety.
• NICE currently states that evidence is insufficient to recommend cannabis medicines routinely for fibromyalgia on the NHS; private prescribing remains the access route.

The growing body of real-world evidence from UK patients is beginning to strengthen the case for larger controlled trials that could ultimately support NHS prescribing for fibromyalgia.

Practical Guidance for UK Fibromyalgia Patients

• Gather a comprehensive medical history including all previous fibromyalgia treatments, duration of use and reasons for discontinuation before your specialist consultation.
• Be specific about your symptom profile: clinicians will want to understand whether pain, sleep, fatigue or cognitive symptoms are your primary concern.
• Starting doses for fibromyalgia are typically low; dose titration over several weeks is standard to minimise side effects and find the optimal therapeutic window.
• Track your symptoms using a pain diary or patient-reported outcome app recommended by your clinic; this data is essential for follow-up appointments and dose adjustments.

Fibromyalgia patients who engage actively with their treatment monitoring tend to achieve better outcomes; regular communication with your prescribing specialist is the single most important factor in long-term success.